GHRH-analogue research peptide · without DAC
CJC-1295 without DAC 10mg
3mL vial
$120AUD
Research use only · Australia-wide dispatch
About this compound
CJC-1295 without DAC, commonly referred to as modified GRF (1–29), is a synthetic analogue of growth hormone–releasing hormone (GHRH). It is investigated for GHRH receptor activity and growth hormone / IGF-1 signalling. It does not contain the drug affinity complex (DAC) and is distinct from the longer-acting CJC-1295 with DAC.
Claims about muscle growth, fat loss, recovery or anti-ageing are not established benefits of this research product. It is not TGA approved for human use. Human use can carry risks, including effects on blood glucose, fluid retention and injection-related complications.
Supplied for in-vitro laboratory research only. Not for human consumption — no health or therapeutic effect is claimed or implied.
Research areas
- GHRH receptor binding assays
- Growth hormone / IGF-1 signalling studies
- Comparative GHRH-analogue research
Specifications
- Compound
- CJC-1295 without DAC (modified GRF 1–29)
- Quantity
- 10mg
- Form
- Sealed 3mL glass vial
- Use
- In-vitro laboratory research only
Not for human consumption. This product is a laboratory research chemical. It is not a therapeutic good, is not TGA approved, and is not intended to diagnose, treat, cure or prevent any disease in humans or animals.
Sold only to qualified researchers aged 18 or over. The buyer accepts sole responsibility for lawful handling, storage and disposal under all applicable Australian laws.
